IP Library Granted Patent US 40,155
Granted Patent E1
US 40,155 · App. 09/724,378 · Granted Mar 18, 2008

Methods for treatment of benign and malignant tumors, including lymphomas, leukemias, and leiomyomas

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 40,155
App. No.
09/724,378
Granted
Mar 18, 2008
Kind
E1
Abstract

In a preferred embodiment, drugs having chemotherapeutic properties which are useful against certain neoplastic disorders with wide safety margins as evidenced by their low toxicity, and molecular actions. Such drugs include as active ingredient(s) one or more N-substituted 2-(1H) pyridone(s) and/or N-substituted 3-(1H) pyridone(s). The compositions of this invention are novel as anti-neoplastic drugs, namely as an agent for treating leukemias, lymphomas, and leiomyomas as agent( s ) for treating benign and malignant tumors, including lymphomas, leukemias, and leiomyomas.

Claims (6)

1. A method of treating lymphomas, leukemias, and/or leiomyomas one or more malignant tumors and/or one or more benign tumors in a laboratory animal or a human, comprising: administering to said laboratory animal or said human an effective dose of a composition including one or more pharmaceutical substances selected from the group consisting of N-substituted 2-(1H) pyridones, N-substituted 3-(1) pyridones, and pharmaceutically acceptable salts thereof, wherein said 2-(1H) pyridones have the following general structural formula:

where: R1 is selected from the group consisting of (1) an alkyl group, with R3 hydrogen, and (2) hydrogen, with R3 consisting of an alkyl group; A is an aryl group; and R2 and R4 are hydrogen; and wherein said 3-(1H) pyridones have the following general structural formula:

where: R2 is selected from the group consisting of (1) an alkyl group, with R3 hydrogen, and (2) hydrogen, with R3 consisting of an alkyl group; A is an aryl group; and R1 and R4 are hydrogen.

2. A method, as defined in claim 1 , wherein: said composition is administered orally or parenterally to said laboratory animal at a rate of from about 250 to about 750 mg/kg of body weight per day.

3. A method, as defined in claim 1 , wherein: said composition is administered orally or parenterally to a said human at a rate of from about 20 to about 60 mg/kg of body weight per day.

4. A method of treating lymphomas, leukemias, and/or leiomyomas one or more malignant tumors and/or one or more benign tumors in a laboratory animal or a human, comprising: administering to said laboratory animal or said human an effective dose of a composition including one or more pharmaceutical substances selected from the group consisting of N-substituted 2-(1H) pyridones, N-substituted 3-(1H) pyridones, and pharmaceutically acceptable salts thereof, said N-substituted 2-(1H) pyridones and said N-substituted 3-(1H) pyridones being selected from the group consisting of: 5-Methyl-1-phenyl-2-(1H) pyridone, 5-Methyl-1-(3-nitrophenyl-2)-(1H) pyridone, 5-Methyl-1-(4′-methoxyphenyl)-2-(1H) pyridone, 5-Methyl-1-p-tolyl-2-(1H) pyridone, 5-Methyl-1-(3′-trifluoromethylphenyl)-2-(1H) pyridone, 1-(4′Chlorophenyl)-5-methyl-2-(1H) pyridone, 5-Methyl-1-(2′-naphthyl)-2-(1H) pyridone, 5-Methyl-1-(1′-naphthyl)-2-(1H) pyridone, 3-Methyl-1-phenyl-2-(1H) pyridone, 6-Methyl-1-phenyl-2-(1H) pyridone, 3,6-Dimethyl-1-phenyl-2-(1H) pyridone, 5-Methyl-1-(2′thienyl)-2-(1H) pyridone, 1-(2′-Furyl)-5-methyl-2-(1H) pyridone, 5-Methyl-1-(5′-quinolyl)-2-(1H) pyridone, 5-Methyl-1-(4′-pyridyl)-2-(1H) pyridone, 5-Methyl-1-(3′-pyridyl)-2-(1H) pyridone, 5-Methyl-1-(2′-pyridyl)-2-(1H) pyridone, 5-Methyl-1-(2′-quinolyl)-2-(1H) pyridone, 5-Methyl-1-(4′-quinolyl)-2-(1H) pyridone, 5-Methyl-1-(2′-thiazolyl)-2-(1H) pyridone, 1-(2′-Imidazolyl-5-methyl-2-(1H) pyridone, 5-Ethyl-1-phenyl-2-(1H) pyridone, 3-Ethyl-1-phenyl-2-(1H) pyridone, 1-Phenyl-2-(1H) pyridone, 1-(4′-Nitrophenyl)-2-(1H) pyridone, 5-Methyl-3-phenyl-1-(2′-thienyl)-2-(1H) pyridone, 5-Methyl-1-phenyl-3-(1H) pyridone, 5-Methyl-1-(4′-methoxyphenyl)-3-(1H) pyridone, 5-Methyl-1-p-tolyl-3-(1H) pyridone, 1-(4′-Chlorophenyl)-5-methyl-3-(1H) pyridone, 5-Methyl-1-(2′-naphthyl)-3-(1H) pyridone, 4-Methyl-1-phenyl-3-(1H) pyridone, 6-Methyl-1-phenyl-3-(1H) pyridone, 5-Methyl-1-(2′-thienyl)-3-(1H) pyridone, 1-(2′-Furyl)-5-methyl-3-(1H) pyridone, 5-Methyl-1-(5′-quinolyl)-3-(1H) pyridone, 5-Methyl-1-(3′-pyridyl)-3-(1H) pyridone, 5-Methyl-1-(2′-pyridyl)-3-(1H) pyridone, 5-Methyl-1-(2′-quinolyl)-3-(1H) pyridone, 5-Ethyl-1-phenyl-3-(1H) pyridone, and 1-Phenyl-3-(1H) pyridone.

Assignments (1)
CERTIFICATE OF CHANGE OF COMPANY'S ADDRESS Recorded Jul 27, 2018
From: INTERMUNE, INC.
To: INTERMUNE, INC.
Reel/Frame 046638/0466 →